PSMA Theranostics Is Poised to Change Prostate Cancer LandscapeMay 22nd 2021
Although research focused on prostate-specific membrane antigen has been ongoing for almost 2 decades, the timing for the emergence of prostate-specific membrane antigen theranostics could not have been any better.
Large NGS Trial Identifies Actionable Alterations in Most Patients With Advanced CancersMay 21st 2021
Potentially clinically actionable genomic alterations were identified in a majority of patients with advanced cancers with next-generation sequencing evaluated in a prospective study.
AB-205 Shows Promise in Patients With Systemic Lymphoma Undergoing HDT-ASCTMay 21st 2021
AB-205 demonstrated robust effects and an encouraging safety profile in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.
Experts in Ovarian Cancer Discuss Targeted Agent Combinations and Disparities in CareMay 20th 2021
The ovarian cancer treatment landscape, including the use of cytotoxic and targeted therapies, is continuously evolving for patients. Recent trials have evaluated PARP inhibitors, antiangiogenic agents, and other targeted therapies, and investigators are looking at strategies to individualize care for patients with ovarian cancer.
Ruxolitinib in GVHD Reveals Lower Risk of Relapse, Longer Duration of ResponseMay 20th 2021
Findings from the phase 3 REACH2 trial demonstrated a lower risk of relapse and longer median duration of response with ruxolitinib versus best available therapy in patients with steroid-refractory acute graft-versus-host disease.
Urothelial Cancer Guidelines Are Updated to Include Immune Checkpoint InhibitorsMay 17th 2021
Immunotherapies are now accepted treatments in the maintenance and second-line settings for patients with metastatic urothelial cancer and in the setting of superficial UC–carcinoma in situ with prior intravesical therapy, according to updated NCCN guidelines
Hybrid International Lung Cancer Congress Focuses on Multimodality TreatmentMay 16th 2021
Roy S. Herbst, MD, PhD, discussed the upcoming conference on July 29-31, which will follow a hybrid format with some faculty and attendees participating online and others participating in person.
Liso-Cel for Patients With R/R LBCL Shows Promising Results in Real-World SettingsMay 15th 2021
Patients with relapsed or refractory aggressive large B-cell lymphoma showed promising results from the administration of lisocabtagene maraleucel in both inpatient and outpatient non–university hospital settings.
Narsoplimab Exceeds Expectations Across High-Risk HSCT-TMA SubtypeMay 14th 2021
Administered narsoplimab in patients with high-risk hematopoietic stem cell transplant– associated thrombotic microangiopathy resulted in a response rate of 61% among all patients treated with the monoclonal antibody
PSMA-Directed Therapies and Diagnostics Expand Their Scope in Prostate CancerMay 14th 2021
With the emergence of therapies that target PSMA, a cell surface transmembrane protein that is overexpressed in most prostate cancer cells, particularly in castration-resistant disease, the ability to detect and treat the disease has been transformed.
The Role of In-Office Next Generation Sequencing to Advance Precision Medicine in Community OncologyMay 13th 2021
The goal of precision medicine is to advance medical and scientific discoveries to offer more tailored, precise, and accurate health interventions to maximize the health benefits for patients.